About SH PIONEER HLDG Company

Shanghai Pioneer Holdings Co., Ltd. (the “Company” or “Pioneer Holdings”) was established in 1996. As a leading comprehensive marketing, promotion and channel management service provider for imported pharmaceuticals and medical device products in China, Pioneer Holdings continues to introduce a series of products representing advanced international technology to the domestic pharmaceutical market to benefit patients. On November 5, 2013, Pioneer Holdings was successfully listed on the main board of the Hong Kong Stock Exchange Limited (“Stock Exchange”) (stock code HK.01345). As an international enterprise with a global perspective, Pioneer Holdings has established stable and mutually beneficial long-term cooperative relationships with many world-renowned pharmaceutical and medical device manufacturers, successfully built a product introduction platform for sustainable development, and established a sales network covering the entire Chinese market. Long-term efforts have created a unique brand foundation for Pioneer Holdings. Pioneer Holdings has established long-term and stable cooperative relationships with many internationally renowned pharmaceutical and medical device manufacturers, including US Alcon, Italy's Alfasigma, Germany's Aenova, Switzerland's Polichem, US Fleet, Liechtenstein Ivoclar Vivadent (Germany Wieland), and US NovaBay Pharmaceuticals, Inc. In Pioneer Holdings' product portfolio, drugs cover treatment fields such as ophthalmology, anti-inflammatory analgesia, cardiovascular system, digestive system, immunomodulation, and gynecology, and medical devices cover various treatment fields such as ophthalmology, cardiology, dentistry, and wound care. Pioneer Holdings is continuously committed to increasing the market value of these brands. Pioneer Holdings has established stable and friendly cooperative relationships with more than 500 mainstream pharmaceutical commercial companies across the country, and Pioneer Holdings' products have achieved effective coverage in tens of thousands of medical institutions and pharmacies across the country. In addition, Pioneer Holdings has gradually launched a global strategy, invested in overseas partner companies or innovative R&D companies, and successively purchased high-end American wound care company NovaBay, Australian medical device company Paragon Care Limited, and DMax Co., a well-known Korean zirconia product manufacturer. , Ltd. (“DMAX”), a portion of its shares. Through overseas investment, Pioneer Holdings has further deepened cooperation with overseas companies, and is also gradually moving towards the goal of becoming an international company. In recent years, Pioneer Holdings has implemented an industrial chain extension and diversification strategy to set up the Chongqing Rongchang production base. This project is an important strategic plan for the Group to transform from a sales enterprise to a comprehensive pharmaceutical enterprise integrating research and development, production and sales. Through a series of measures, the Group hopes to respond to the national industrial development policy, turn the Rongchang Production Base (“Rongchang Production Base”) into an open technology platform, introduce new technologies and products, localize high-quality imported products, and give full play to the Group's comprehensive capabilities and advantages in integrating production and marketing, so as to continuously improve the market competitiveness of products and the Group's profitability.